Trial Outcomes & Findings for PreHospital Air Medical Plasma Trial (NCT NCT01818427)

NCT ID: NCT01818427

Last Updated: 2021-04-08

Results Overview

All cause 30 day mortality using imputation for those with missing 30 day mortality.

Recruitment status

COMPLETED

Study phase

PHASE3

Target enrollment

523 participants

Primary outcome timeframe

30 days

Results posted on

2021-04-08

Participant Flow

Participant milestones

Participant milestones
Measure
Plasma
infusion of 2 units of plasma infusion of 2 units of plasma: infusion of 2 units of plasma
Standard Air Medical Care
control group
Overall Study
STARTED
239
284
Overall Study
COMPLETED
230
271
Overall Study
NOT COMPLETED
9
13

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

PreHospital Air Medical Plasma Trial

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Plasma
n=230 Participants
infusion of 2 units of plasma infusion of 2 units of plasma: infusion of 2 units of plasma
Standard Air Medical Care
n=271 Participants
control group
Total
n=501 Participants
Total of all reporting groups
Age, Continuous
44 years
n=99 Participants
46 years
n=107 Participants
45 years
n=206 Participants
Sex: Female, Male
Female
66 Participants
n=99 Participants
71 Participants
n=107 Participants
137 Participants
n=206 Participants
Sex: Female, Male
Male
164 Participants
n=99 Participants
200 Participants
n=107 Participants
364 Participants
n=206 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
Race (NIH/OMB)
Asian
0 Participants
n=99 Participants
1 Participants
n=107 Participants
1 Participants
n=206 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
Race (NIH/OMB)
Black or African American
14 Participants
n=99 Participants
29 Participants
n=107 Participants
43 Participants
n=206 Participants
Race (NIH/OMB)
White
207 Participants
n=99 Participants
228 Participants
n=107 Participants
435 Participants
n=206 Participants
Race (NIH/OMB)
More than one race
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
Race (NIH/OMB)
Unknown or Not Reported
9 Participants
n=99 Participants
13 Participants
n=107 Participants
22 Participants
n=206 Participants
Region of Enrollment
United States
230 Participants
n=99 Participants
271 Participants
n=107 Participants
501 Participants
n=206 Participants

PRIMARY outcome

Timeframe: 30 days

Population: 10 patients in each arm were lost to follow-up for 30-day mortality and 22 patients total, 8 in the plasma arm and 12 in the standard care arm withdrew consent and 1 patient in each arm was a prisoner and could not be included in the analysis cohort. We compared 30-day mortality using a two sided pooled z test with continuity correction.

All cause 30 day mortality using imputation for those with missing 30 day mortality.

Outcome measures

Outcome measures
Measure
Plasma
n=220 Participants
infusion of 2 units of plasma infusion of 2 units of plasma: infusion of 2 units of plasma
Standard Air Medical Care
n=261 Participants
control group
Our Primary Outcome for the Proposal Will be 30 Day Mortality
53 Participants
89 Participants

SECONDARY outcome

Timeframe: at twenty four hours

24-hour blood transfusion requirements will be determined by recording blood volume (mls) and number of Units transfused from the time of trauma bay arrival or upon completion of pre-hospital initiated plasma infusion. For survival bias analysis, volumes and number of blood transfusion Units received at 3, 6, 12, and 18 hours will also be recorded.

Outcome measures

Outcome measures
Measure
Plasma
n=230 Participants
infusion of 2 units of plasma infusion of 2 units of plasma: infusion of 2 units of plasma
Standard Air Medical Care
n=271 Participants
control group
Twenty Four-Hour Blood Transfusion Requirements
3 units of blood
Interval 0.0 to 7.0
4 units of blood
Interval 1.0 to 9.0

SECONDARY outcome

Timeframe: during hospitalization

In hospital mortality will be prospectively recorded from the time of trauma bay arrival. Over the first 24 hours we will document and record the time of death in hours, while after the 24 hour time point, we will document and record the time of death in days from arrival. We suspect that patients in hemorrhagic shock will have a significant percentage of mortality occurring in the first 24 hour period.

Outcome measures

Outcome measures
Measure
Plasma
n=230 Participants
infusion of 2 units of plasma infusion of 2 units of plasma: infusion of 2 units of plasma
Standard Air Medical Care
n=271 Participants
control group
In-hospital Mortality
51 Participants
88 Participants

SECONDARY outcome

Timeframe: during hospitalization

Organ dysfunction will be evaluated via a well-validated scoring system referred to as the Multiple Organ Dysfunction Score (MODScore). Patients who are never admitted to the ICU or those with a length of ICU stay of less than 48 hours will be considered to have a MODScore of 0. A summary of the MODScore may be calculated by summing the worst scores of each of the individual systems over the course of the ICU stay (Table 1). A summary MODScore \> 5 will be classified as multiple organ failure (MOF). Scores will be determined daily up until post injury day 28 or ICU discharge.

Outcome measures

Outcome measures
Measure
Plasma
n=230 Participants
infusion of 2 units of plasma infusion of 2 units of plasma: infusion of 2 units of plasma
Standard Air Medical Care
n=271 Participants
control group
Multiple Organ Failure
145 Participants
156 Participants

SECONDARY outcome

Timeframe: hospitalization

Development of ALI will be assessed which includes: 1) bilateral infiltrates on chest x-ray, 2) a capillary wedge pressure \< 18mmHg, and 3) Pao2/Fio2 ratio \< 300 via blood gas analysis. In those patients without a Swan-Ganz catheter to determine capillary wedge pressure, the absence of signs of, or clinical concern, for elevated left sided atrial pressures will be used for the diagnosis. All patients who remain intubated beyond the first 24 hours post-injury will be evaluated using blood gas analysis and chest x-ray evaluation. Those patients who remain intubated at 48 hours through 7 days will be reevaluated for this outcome at these time points. The diagnosis of TRALI will be defined as when ALI occurs within the first 6 hours from arrival at the trauma center as it is clinically defined.

Outcome measures

Outcome measures
Measure
Plasma
n=230 Participants
infusion of 2 units of plasma infusion of 2 units of plasma: infusion of 2 units of plasma
Standard Air Medical Care
n=271 Participants
control group
Acute Lung Injury (ALI) and Transfusion Related Acute Lung Injury (TRALI)
48 Participants
50 Participants

Adverse Events

Plasma

Serious events: 1 serious events
Other events: 5 other events
Deaths: 53 deaths

Standard Air Medical Care

Serious events: 2 serious events
Other events: 2 other events
Deaths: 89 deaths

Serious adverse events

Serious adverse events
Measure
Plasma
n=220 participants at risk
infusion of 2 units of plasma infusion of 2 units of plasma: infusion of 2 units of plasma
Standard Air Medical Care
n=261 participants at risk
control group
Blood and lymphatic system disorders
tranfusion-related reaction
0.45%
1/220 • Number of events 1 • 30 days
0.00%
0/261 • 30 days
Blood and lymphatic system disorders
sepsis
0.00%
0/220 • 30 days
0.38%
1/261 • Number of events 1 • 30 days
Respiratory, thoracic and mediastinal disorders
adult respirator distress syndrome
0.00%
0/220 • 30 days
0.38%
1/261 • Number of events 1 • 30 days

Other adverse events

Other adverse events
Measure
Plasma
n=220 participants at risk
infusion of 2 units of plasma infusion of 2 units of plasma: infusion of 2 units of plasma
Standard Air Medical Care
n=261 participants at risk
control group
Blood and lymphatic system disorders
allergic reation
0.91%
2/220 • Number of events 2 • 30 days
0.00%
0/261 • 30 days
Blood and lymphatic system disorders
Anaphylaxis
0.45%
1/220 • Number of events 1 • 30 days
0.00%
0/261 • 30 days
Blood and lymphatic system disorders
fever
0.00%
0/220 • 30 days
0.38%
1/261 • Number of events 1 • 30 days
Blood and lymphatic system disorders
hypotension
0.45%
1/220 • Number of events 1 • 30 days
0.00%
0/261 • 30 days
Blood and lymphatic system disorders
pain
0.00%
0/220 • 30 days
0.38%
1/261 • Number of events 1 • 30 days
Blood and lymphatic system disorders
urticaria
0.45%
1/220 • Number of events 1 • 30 days
0.00%
0/261 • 30 days

Additional Information

Dr. Jason Sperry

University of Pittsburgh

Phone: 412 6922850

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place